2020 / 05

Next Paper
DOI: 10.24075/brsmu.2020.067

ORIGINAL RESEARCH

Immunohistochemical expression of Nanog protein in prostate cancer cells of distinct grade groups

Kudryavtsev GYu1,3, Kudryavtseva LV1, Mikhaleva LM2, Kudryavtsevа YaYu1, Solovyeva NA1, Osipov VA3, Babichenko II1
About authors

1 Peoples’ Friendship University of Russia, Moscow, Russia

2 Research Institute of Human Morphology, Moscow, Russia

3 Hospital for War Veterans № 2, Moscow, Russia

Correspondence should be addressed: Georgy Yu. Kudryavtsev
Baikalskaya, 35, apt. 216, Moscow, 107207; ur.liam@ahsogk

About paper

Compliance with ethical standards: the study was approved by the Ethics Committee of Medical Institute of the Peoples' Friendship University of Russia (protocol № 13 dated December 19, 2019); the study design was consistent with the Declaration of Helsinki guidelines regarding the research involving identifiable human tissue samples. The informed consent was submitted by all patients.

Author contribution: Kudryavtsev GYu, Kudryavtsevа YaYu, Solovyeva NA — literature survey, manuscript writing; Kudryavtseva LV, Osipov VA — statistical data processing; Mikhaleva LM — sample collection and processing; Babichenko II — study concept and design.

Received: 2020-10-06 Accepted: 2020-10-20 Published online: 2020-10-31
|
  1. Kaprin АD, Starinskiy VV, Petrova GV, editors. Malignant tumors in Russia in 2018 (morbidity and fatality). Мoscow: FGBU «Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institute im. P.A. Gertsena» — filial FGBU «Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr» Minzdrava Rossii, 2019; 250 p. Russian.
  2. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: аn analysis of time trends overall and by age group. Int J Cancer. 2016; 138 (6): 1388–400.
  3. Heidegger I, Heidenreich A, Pfister D. New biomarkers for selecting the best therapy regimens in metastatic castration-resistant prostate cancer. Target Oncol. 2017; 12 (1): 37–45.
  4. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al (eds). SEER Cancer Statistics Review, 1975- 2006, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2006/
  5. Bell KJL, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: а systematic review of autopsy studies. Int J Cancer. 2015; 137 (7): 1749–57.
  6. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975-2013, National Cancer Institute. National Cancer Institute. Bethesda, 2016. Available from: https://seer.cancer.gov/csr/1975_2014/.
  7. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤ 4.0 ng per Milliliter. N Engl J Med. 2004; 350 (22): 2239–46.
  8. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14 (3): 275–91. DOI: 10.1016/j.stem.2014.02.006.
  9. Aguilar-Gallardo C, Simón C. Cells, stem cells, and cancer stem cells. Seminars in Reproductive Medicine. 2013; 31 (01): 005– 013. DOI: 10.1055/s-0032-1331792.
  10. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730–7. DOI: 10.1038/nm0797-730.
  11. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003; 113: 643– 55. PubMed PMID: 12787505.
  12. Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113: 631–42.
  13. Gawlik-Rzemieniewska N, Bednarek I. The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells. Cancer Biol Ther. 2015; 17 (1): 1–10. DOI:10.108 0/15384047.2015.1121348.
  14. Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol. 2005; 6: 872–84.
  15. Gong S, Li Q, Jeter CR, Fan Q, Tang DG, Liu B. Regulation of NANOG in cancer cells. Mol Carcinog. 2015; 54 (9): 679–87. DOI: 10.1002/mc.22340.
  16. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21 (20): 3798–807.
  17. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017; 23 (10): 1124–34. DOI:10.1038/nm.4409.
  18. Zhang J, Espinoza LA, Kinders RJ, et al. NANOG modulates stemness in human colorectal cancer. Oncogene. 2013 Sep 12; 32 (37): 4397–405.
  19. Niu CS, Li DX, Liu YH, Fu XM, Tang SF, Li J. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep. 2011; 26 (3): 593–601.
  20. Ibrahim EE, Babaei-Jadidi R, Saadeddin A, et al. Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms. Stem Cells. 2012; 30 (10): 2076–87.
  21. Grubelnik G, Boštjančič E, Pavlič A, Kos M, Zidar N. NANOG expression in human development and cancerogenesis. Exp Biol Med. 2020; 245 (5): 456–64.
  22. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct- 4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008; 14 (13): 4085–95.
  23. Gillis AJ, Stoop H, Biermann K, et al. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. Int J Androl. 2011; 34 (4 Pt 2): e160–e174.
  24. Chiou SH, Wang ML, Chou YT, et al. Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010; 70 (24): 10433–4.
  25. Han J, Zhang F, Yu M, et al. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett. 2012; 321 (1): 80–8.
  26. Choi SC, Choi JH, Park CY, Ahn CM, Hong SJ, Lim DS. Nanog regulates molecules involved in stemness and cell cycle-signaling pathway for maintenance of pluripotency of P19 embryonal carcinoma stem cells. J Cell Physiol. 2012; 227 (11): 3678–92.